- Visibility 375 Views
- Downloads 567 Downloads
- Permissions
- DOI 10.18231/j.ijceo.v.11.i.3.17
-
CrossMark
- Citation
Clinical evaluation of calcium dobesilate in diabetic retinopathy patients
- Author Details:
-
Kriti Aditya
-
Farhat Abrar *
-
Nazia Jamal
-
Shivani Kinha1
Background: Diabetic Retinopathy (DR) is a common complication of diabetes, characterized by retinal microvascular changes that can lead to vision loss. Calcium dobesilate, a vascular-regulating medication, may help manage DR by reducing inflammation and capillary permeability.
Aim: This study aimed to evaluate the effects of oral calcium dobesilate on pro-inflammatory markers in patients with diabetic retinopathy.
Materials and Methods: A prospective interventional study was conducted from February 2023 to March 2024 at Netaji Subash Chandra Bose Subharti Medical College, Meerut. Fifty patients with type 2 diabetes were divided into three groups: Group A (17 patients with DR treated with calcium dobesilate), Group B (17 patients with DR receiving a placebo), and Group C (16 diabetic patients without retinopathy). Serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) were measured at baseline and after 12 weeks of treatment.
Results: After 12 weeks, Group A showed a significant reduction in IL-6 (from 4.82 pg/ml to 3.88 pg/ml, p = 0.039) and TNF-α levels (from 27.73 pg/ml to 24.01 pg/ml, p = 0.038), compared to Group B, which had no significant changes. CRP levels decreased in Group A (from 3.15 mg/L to 2.61 mg/L) but increased slightly in Group B.
Conclusion: Calcium dobesilate effectively reduces pro-inflammatory markers in diabetic retinopathy patients, suggesting its potential as a therapeutic option. Further studies are needed to confirm these findings and assess long-term outcomes.
References
- Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–8.
- Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16(3):242–60.
- Wong TY, Cheung CMG, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012.
- Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016:2156273.
- Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, et al; DX-Retinopathy Study Group. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double- blind study. Graefes Arch Clin Exp Ophthalmol . 2006;244(12):1591–600.
- Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology. 2010;25(2):66–71.
- Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol. 1997;121(4):711.
- Graber R, Farine JC, Losa GA. Calcium dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis. 1998;3(1):41–9.
- Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol. 2001;428(2):277–86.
- Opreanu M, Lydic TA, Reid GE, McSorley KM, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by Aditya et al. / Indian Journal of Clinical and Experimental Ophthalmology 2025;11(3):466–471 471 docosahexaenoic acid. Invest Ophthalmol Vis Sci. 2010;51(6):3253–
- Tan Y, Fukutomi A, Sun MT, Durkin S, Gilhotra J, Chan WO. Anti- VEGF crunch syndrome in proliferative diabetic retinopathy: a review. Surv Ophthalmol. 2021;66(6):926–32.
- Rodríguez ML, Pérez S, Mena-Mollá S, Desco MC, Ortega ÁL. Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies. Oxid Med Cell Longev. 2019:4940825.
- Larsson LI, Alm A, Lithner F, Dahlen G, Bergström R. The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umeå. Acta Ophthalmol Scand. 1999;77(5):585–91.
- Sachdev N, Sahni A. Association of systemic risk factors with the severity of retinal hard exudates in a north Indian population with type 2 diabetes. J Postgrad Med. 2010;56(1):3–6.
- Haas A, Trummer G, Eckhardt M, Schmut O, Uyguner I, Pfeiffer KP. [Effect of calcium dobesilate on progression of diabetic retinopathy]. [Article in German]. Klin Monbl Augenheilkd. 1995;207(1):17–21.
- Költringer P, Eber O, Rothlauer W, Klima G, Lind P, Langsteger W, et al. Calcium dobesilate and its effects on hemorheology and microcirculation. Int J Clin Pharmacol, Ther Toxicol. 1988;26(10):500–2.
- Dittmar P. Photocoagulation given additional benefit by calciumdobesilate (author's transl). Klinische Monatsblatter fur Augenheilkunde. 1979;174(5):753–5.
- Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol. 1990;14(2):81–8.
- Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res. 1991;23(1):12–20.
- Hernández-Da Mota SE, Soto-Bahena JJ, Viveros-Sandoval ME, Cardiel-Ríos M. [Pro-inflammatory serum cytokines in diabetic retinopathy]. [Article in Spanish]. Cir Cir. 2015;83(2):100–6.
- Almutairi NM, Alahmadi S, Alharbi M, Gotah S, Alharbi M. The association between HbA1c and other biomarkers with the prevalence and severity of diabetic retinopathy. Cureus. 2021;13(1):e12520.
- Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2009;373(9672):1364–71.
How to Cite This Article
Vancouver
Aditya K, Abrar F, Jamal N, Kinha1 S. Clinical evaluation of calcium dobesilate in diabetic retinopathy patients [Internet]. Indian J Clin Exp Ophthalmol. 2025 [cited 2025 Oct 23];11(3):466-471. Available from: https://doi.org/10.18231/j.ijceo.v.11.i.3.17
APA
Aditya, K., Abrar, F., Jamal, N., Kinha1, S. (2025). Clinical evaluation of calcium dobesilate in diabetic retinopathy patients. Indian J Clin Exp Ophthalmol, 11(3), 466-471. https://doi.org/10.18231/j.ijceo.v.11.i.3.17
MLA
Aditya, Kriti, Abrar, Farhat, Jamal, Nazia, Kinha1, Shivani. "Clinical evaluation of calcium dobesilate in diabetic retinopathy patients." Indian J Clin Exp Ophthalmol, vol. 11, no. 3, 2025, pp. 466-471. https://doi.org/10.18231/j.ijceo.v.11.i.3.17
Chicago
Aditya, K., Abrar, F., Jamal, N., Kinha1, S.. "Clinical evaluation of calcium dobesilate in diabetic retinopathy patients." Indian J Clin Exp Ophthalmol 11, no. 3 (2025): 466-471. https://doi.org/10.18231/j.ijceo.v.11.i.3.17